- Raised $50M Series B led by OrbiMed Advisors, Dec 2025
- Raised $8M Seed round led by Menomadin Foundation, Mar 2020
- Raised $600k grant, Dec 2018
About
Biobeat is a med-tech company providing FDA-cleared, cuffless blood pressure monitoring. The small, non-invasive sensor is placed onto the patient’s chest for 24 hours, and the measurements are taken through our proprietary patented PPG sensor. The technology not only allows for blood pressure to be taken, but also extracts heart rate, and cardiac output. The device and automated platform deliver a detailed report to the clinician, immediately after the patient has completed the test. This allows for quick evaluation and treatment plans, and also enables physicians to make proper adjustments on current treatment plans based on the quantitative measures and trends that the blood pressure monitoring solution provides.
The Biobeat sensor eliminates white coat and masked hypertension by using a cuffless test. White coat hypertension is a common barrier in ABPM testing, as patients often become stressed when the cuff inflates. However, with Biobeat, patients often forget they are wearing the sensor and do not feel when the readings are being taken. This allows them to go about their daily lives without interruption.
Funding history · 6 rounds · $58.6M total
Headcount over time
Offices
Show all offices (1 more)
- United States
Q&A
- What is Biobeat's primary business?
- Biobeat is a med-tech company that provides FDA-cleared, cuffless blood pressure monitoring using a small, non-invasive sensor placed on the patient’s chest for 24 hours. The technology also extracts heart rate and cardiac output.
- When was Biobeat founded?
- Biobeat was founded in March 2016.
- What is the total amount of funding Biobeat has raised to date?
- Biobeat has raised a total of $68,600,000 in funding.
- Who were the lead investors in Biobeat's January 2026 funding round?
- In January 2026, Biobeat raised $50,000,000 with Ally Bridge Group and OrbiMed participating in the round.
- Which company invested in Biobeat in September 2023?
- In September 2023, Best Buy Health invested $7,000,000 in Biobeat.
- Who are the co-founders of Biobeat?
- The co-founders of Biobeat are Arik Ben Ishay (CEO), Johanan May (Co-founder & CTO), and Israel Sarussi (Co-founder & VP R&D).
- What is Biobeat's current funding stage?
- Biobeat is currently in its Series B funding stage.
Team · 14
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | bio-beat.com |
|---|---|
| linkedin.com/company/17969237 | |
| YouTube | youtube.com/channel/UCw58hx1AukX-8bBJY5aHrtw |
Identifiers & details
| Legal name | Biobeat Technologies, Ltd. |
|---|---|
| Founded | 2016-3 |
| Employees (exact) | 45 |
| Offices | United States |
Radar intelligence
Patents
| EPO | 8 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | bio-beat.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 515356418 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2016-02-02 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 12 — other (1), shares_capital (4), people (3), charge (1), annual_report (3) |
| Registered address | דיין משה 10 פתח תקווה |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-29 | שינוי בתקנון |
| 2026-06-22 | הקצאת מניות |
| 2026-02-18 | עדכון דירקטורים-הוספת דירקטור |
| 2026-02-18 | עדכון דירקטורים-הסרת דירקטור |
| 2026-02-15 | עדכון בעלי תפקידים |
| 2026-05-13 | סילוק שעבוד |
| 2026-01-13 | שינוי בהרכב הון - מניות-פיצול מניה |
| 2026-01-11 | הגדלה של הון רשום |
| 2026-01-06 | שינוי בהרכב הון - מניות-הפחתת הון מוקצה |
| 2026-07-02 | דו~ח שנתי-עדכון כתובת |
| 2026-07-02 | דו~ח שנתי-עדכון בעלי מניות |
| 2026-07-02 | דו~ח שנתי-שינוי בהוראות בתקנון |